Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CK
MCID: CHK001
MIFTS: 55

Chikungunya (CK)

Categories: Blood diseases, Bone diseases, Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Chikungunya

About this section

MalaCards integrated aliases for Chikungunya:

Name: Chikungunya 12 75 53 59 43 15
Chikungunya Fever 12 53 3 72
Arbovirus a Chikungunya Type 53
Chikungunya Virus Infection 53
Chikv Infection 53
Syndrome, Ck 40
Chik 53
Ck 53

Characteristics:

Orphanet epidemiological data:

59
chikungunya
Prevalence: <1/1000000 (France),<1/1000000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Blood diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:0050012
ICD10 33 A92.0
ICD10 via Orphanet 34 A92.0
UMLS via Orphanet 73 C0008055
Orphanet 59 ORPHA324625
UMLS 72 C0008055
Sources

Summaries for Chikungunya

About this section
MedlinePlus : 43 Chikungunya is a virus that spread by the same kinds of mosquitoes that spread dengue and Zika virus. Rarely, it can spread from mother to newborn around the time of birth. It may also possibly spread through infected blood. There have been outbreaks of chikungunya virus in Africa, Asia, Europe, the Indian and Pacific Oceans, the Caribbean, and Central and South America. Most people who are infected will have symptoms, which can be severe. They usually start 3-7 days after being bitten by an infected mosquito. The most common symptoms are fever and joint pain. Other symptoms may include headache, muscle pain, joint swelling, and rash. Most people feel better within a week. In some cases, however, the joint pain may last for months. People at risk for more severe disease include newborns, older adults, and people with diseases such as high blood pressure, diabetes, or heart disease. A blood test can show whether you have chikungunya virus. There are no vaccines or medicines to treat it. Drinking lots of fluids, resting, and taking non-aspirin pain relievers might help. The best way to prevent chikungunya infection is to avoid mosquito bites: Use insect repellent Wear clothes that cover your arms, legs, and feet Stay in places that have air conditioning or that use window and door screens Centers for Disease Control and Prevention

MalaCards based summary : Chikungunya, also known as chikungunya fever, is related to dengue virus and cardiogenic shock, and has symptoms including fever, arthralgia and maculopapular rash. An important gene associated with Chikungunya is OAS3 (2'-5'-Oligoadenylate Synthetase 3), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs chloroquine and Contraceptive Agents, Male have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and t cells, and related phenotype is immune system.

Disease Ontology : 12 A viral infectious disease that results in infection located in joint, has material basis in Chikungunya virus, which is transmitted by Aedes mosquito bite. The infection has symptom fever, has symptom arthralgia, and has symptom maculopapular rash.

CDC : 3 Chikungunya virus is spread to people by the bite of an infected mosquito. The most common symptoms of infection are fever and joint pain. Other symptoms may include headache, muscle pain, joint swelling, or rash. Outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, chikungunya virus was found for the first time in the Americas on islands in the Caribbean. There is a risk that the virus will be imported to new areas by infected travelers. There is no vaccine to prevent or medicine to treat chikungunya virus infection. Travelers can protect themselves by preventing mosquito bites. When traveling to countries with chikungunya virus, use insect repellent, wear long sleeves and pants, and stay in places with air conditioning or that use window and door screens.

Wikipedia : 75 Chikungunya is an infection caused by the chikungunya virus (CHIKV). Symptoms include fever and joint... more...

Sources

Related Diseases for Chikungunya

About this section

Diseases related to Chikungunya via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 567)
# Related Disease Score Top Affiliating Genes
1 dengue virus 33.3 RSAD2 OAS3 DDX58
2 cardiogenic shock 30.7 TNF IL6
3 anterior uveitis 30.7 IL6 CCL2
4 yellow fever 30.7 RSAD2 IL6 CCL5 CCL2
5 japanese encephalitis 30.5 TNF DDX58 CCL5
6 west nile encephalitis 30.5 OAS3 BST2
7 ebola hemorrhagic fever 30.0 DDX58 BST2
8 filariasis 29.9 TNF IL6 CCL5
9 toxic shock syndrome 29.7 TNF IL6 IL1B
10 synovitis 29.7 TNF IL6 IL1B
11 atherosclerosis susceptibility 29.6 TNF IL6 CCL2
12 encephalitis 29.6 RSAD2 IL1B DDX58 CCL5 CCL2
13 kawasaki disease 29.6 TNF IL6 CCL2
14 arthritis 29.6 TNF IL6 IL1B CCL2
15 pericarditis 29.4 TNF IL6 IL1B
16 gingivitis 29.4 TNF IL6 IL1B
17 leptospirosis 29.4 TNF IL6 IL1B CCL2
18 perinatal necrotizing enterocolitis 29.3 TNF IL6 IL1B
19 acute respiratory distress syndrome 29.3 TNF IL6 IL1B
20 toxoplasmosis 29.3 TNF IL6 IL1B
21 cerebral palsy 29.2 TNF IL6 IL1B
22 gastrointestinal system disease 29.2 TNF IL6 IL1B
23 adult-onset still's disease 29.1 TNF IL6 IL1B
24 aphthous stomatitis 29.1 TNF IL6 IL1B
25 graft-versus-host disease 29.1 TNF IL6 IL1B
26 ulcerative colitis 29.0 TNF IL6 IL1B
27 chronic fatigue syndrome 29.0 TNF IL6 IL1B
28 psoriatic arthritis 29.0 TNF IL6 IL1B
29 pertussis 29.0 TNF IL6 IL1B
30 neuritis 29.0 TNF IL1B CCL5 CCL2
31 myocardial infarction 29.0 TNF IL6 IL1B CCL5 CCL2
32 nervous system disease 29.0 TNF IL6 IL1B CCL2
33 central nervous system disease 28.9 TNF IL6 IL1B CCL2
34 dengue shock syndrome 28.9 TNF IL6 IL1B CCL2
35 pyelonephritis 28.8 TNF IL6 IL1B CCL2
36 stomatitis 28.8 TNF RSAD2 IL1B DDX58 BST2
37 chorioamnionitis 28.7 TNF IL6 IL1B CCL2
38 meningitis 28.7 TNF IL6 IL1B CCL2
39 bacterial infectious disease 28.6 TNF IL6 IL1B CCL2
40 viral infectious disease 28.6 TNF MAVS IL6 IL1B DDX58 CCL5
41 malaria 28.5 TNF IL6 IL1B CCL5 CCL2
42 rheumatoid arthritis 28.3 TNF IL6 IL1B CCL5 CCL2
43 human immunodeficiency virus type 1 28.2 TNF IL6 CCL5 CCL2 BST2
44 proteasome-associated autoinflammatory syndrome 1 28.2 TNF IL6 IL1B CCL5 CCL2
45 lung disease 27.9 TNF IL6 IL1B CCL5 CCL2
46 asthma 27.7 TNF IL6 IL1B CCL5 CCL2
47 systemic lupus erythematosus 27.2 UBE2L3 TNF IL6 IL1B CCL5 CCL2
48 ck syndrome 12.8
49 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 11.5
50 neuroleptic malignant syndrome 11.5

Graphical network of the top 20 diseases related to Chikungunya:



Diseases related to Chikungunya
Sources

Symptoms & Phenotypes for Chikungunya

About this section

Symptoms:

12
  • • fever
  • • arthralgia
  • • maculopapular rash

UMLS symptoms related to Chikungunya:


fever, pruritus

MGI Mouse Phenotypes related to Chikungunya:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.28 CCL2 CCL5 DDX58 IL1B IL6 MAVS
Sources

Drugs & Therapeutics for Chikungunya

About this section

Drugs for Chikungunya (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
2 Contraceptive Agents, Male Phase 3
3 Spermatocidal Agents Phase 3
4 Contraceptive Agents Phase 3
5 Nonoxynol Phase 3
6 Anti-Inflammatory Agents, Non-Steroidal Phase 3
7 Anti-Inflammatory Agents Phase 3
8 Antirheumatic Agents Phase 3
9 Analgesics Phase 3
10 Peripheral Nervous System Agents Phase 3
11 Chloroquine diphosphate Phase 3 50-63-5
12 Anti-Infective Agents Phase 3
13 Antiparasitic Agents Phase 3
14 Analgesics, Non-Narcotic Phase 3
15 Anthelmintics Phase 3
16 Antimalarials Phase 3
17 Antiprotozoal Agents Phase 3
18
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
19
Aluminum sulfate Approved Phase 2 10043-01-3
20 gamma-Globulins Phase 1, Phase 2
21 Immunoglobulins, Intravenous Phase 1, Phase 2
22 Rho(D) Immune Globulin Phase 1, Phase 2
23 Antibodies Phase 2
24 Immunoglobulins Phase 2
25 Pharmaceutical Solutions Phase 2
26 Vaccines Phase 2
27 Immunologic Factors Phase 2
28 Antibodies, Monoclonal Phase 1
29
Prednisolone phosphate Approved, Vet_approved 302-25-0
30
Methotrexate Approved 1959-05-2, 59-05-2 126941
31
Methylprednisolone Approved, Vet_approved 83-43-2 6741
32
leucovorin Approved 58-05-9 143 6006
33
Methylprednisolone hemisuccinate Approved 2921-57-5
34
Pantoprazole Approved 102625-70-7 4679
35
Prednisolone Approved, Vet_approved 50-24-8 5755
36
Mechlorethamine Approved, Investigational 51-75-2 4033
37
Mebendazole Approved, Vet_approved 31431-39-7 4030
38
Albendazole Approved, Vet_approved 54965-21-8 2082
39
Ivermectin Approved, Investigational, Vet_approved 70288-86-7 6474909
40
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
41
Prednisolone hemisuccinate Experimental 2920-86-7
42 Folic Acid Antagonists
43 Prednisolone acetate
44 Methylprednisolone Acetate
45 Vitamin B9
46 Nucleic Acid Synthesis Inhibitors
47 Folate
48 Vitamin B Complex
49 Immunosuppressive Agents
50 Dermatologic Agents

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study Recruiting NCT03037164 Phase 3
2 CuraChik : Double Blind Placebo-controlled Randomized Trial : Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease. Terminated NCT00391313 Phase 3 Chloroquine
3 Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Unknown status NCT02230163 Phase 1, Phase 2
4 Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Completed NCT02562482 Phase 2
5 Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers Completed NCT02861586 Phase 2
6 Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area Completed NCT03101111 Phase 2
7 Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in Previously Exposed Adults Recruiting NCT03807843 Phase 2
8 Observer Blinded, Randomised Study to Investigate Safety, Tolerability and Long-term Immunogenicity of Different Dose Regimens and Formulations of MV-CHIK in Healthy Volunteers Active, not recruiting NCT03635086 Phase 2
9 A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted) Active, not recruiting NCT03483961 Phase 2
10 A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus naïve Controls. Not yet recruiting NCT03992872 Phase 2
11 A Phase 1, Double Blinded, Placebo Controlled, Dose Comparison Trial to Evaluate the Safety, Immunogenicity and Schedule of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults Completed NCT03028441 Phase 1
12 VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Completed NCT01489358 Phase 1
13 Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine Completed NCT03055000 Phase 1
14 A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults Recruiting NCT03829384 Phase 1
15 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers Given as a Standalone Vaccine or Co-administered With the Chikungunya Virus (CHIKV) Candidate Vaccine ChAdOx1 Chik Recruiting NCT04015648 Phase 1
16 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Chikungunya Virus (CHIKV) Vaccine ChAdOx1 Chik in Healthy Adult Volunteers Active, not recruiting NCT03590392 Phase 1
17 A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non Endemic Chikungunya Region Active, not recruiting NCT03325075 Phase 1
18 A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years Active, not recruiting NCT03382964 Phase 1
19 Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya Unknown status NCT02281123
20 A Pilot Study Examining for the Presence of Fecal Coliforms in Peruvian Water Sources and the Association of Tropical Diseases Within Peru Unknown status NCT03078894
21 Investigate the Prevalence of Serum Chikungunya Virus Infection, and Against Those Suspected Dengue Fever, Chikungunya Disease-related Tests Conducted Completed NCT02174341
22 Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors Completed NCT02794181
23 Transcranial Direct Current Stimulation (tDCS) and Its Therapeutic Effects in Chikungunya Fever Completed NCT02993952
24 Efficacy of Starting Methotrexate Early in Chikungunya Arthritis:A 24 Week Randomized Controlled Open Label Crossover Trial Completed NCT03058471 Methotrexate;NSAID;Steroids
25 Effects of Auriculotherapy on Pain and Functional Capacity of Individuals With Chikungunya Fever Completed NCT03090685
26 Epidémie de Chikungunya à l'île de La Réunion : Effet à Dix Ans de l'Infection Sur la qualité de Vie Dans la Cohorte TELECHIK Completed NCT02901509
27 Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection Completed NCT02553369
28 A Pilot Study of the Pathogenesis of Chikungunya Arthritis in the Americas Completed NCT02463968
29 A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components Completed NCT02305732
30 The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01) Completed NCT02831699
31 Quantification of GADD34 Expression in Rheumatoid Arthritis Completed NCT02401165
32 Defining Skin Immunity of a Bite of Key Insect Vectors in Humans Completed NCT03641339
33 Pilot Survey of Dengue Fever in Solomon Islands Completed NCT01868399
34 Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine Completed NCT03158233
35 Spatial Repellent Products for Control of Vector-borne Diseases - Dengue Completed NCT03553277
36 Rash Accompanied by Three or More Dengue-like Symptoms During Pregnancy and Microcephaly: Case-control Study Completed NCT02741882
37 Causes of Acute Undifferentiated Fever in Outpatients in the Democratic Republic of Congo Completed NCT02656862
38 The Sero-prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands Completed NCT01080989
39 Clinical Effectiveness of Standard Versus Pathogen-reduced Buffy Coat-derived Platelet Concentrates in Plasma in Hemato-oncological Patients. Completed NCT02783313
40 Genetic Factors and Immunological Determinism of Persistent Consequences of Chikungunya Fever: Genome-wide Association Study Recruiting NCT03690648
41 Effect of a Resistance Exercise Program on the Functionality of Individuals With Chikungunya Fever: Randomized Clinical Trial Recruiting NCT03702348
42 World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia Recruiting NCT03631719
43 Applying Wolbachia to Eliminate Dengue (AWED): A Non-blinded Cluster Randomised Controlled Trial to Assess the Efficacy of Wolbachia-infected Mosquito Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia Recruiting NCT03055585
44 Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r Recruiting NCT01099852
45 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Recruiting NCT03206541
46 World Mosquito Program Noumea - Human Sample Component Recruiting NCT03552094
47 Clinical Evaluation of the FilmArray® Global Fever (GF) Panel Recruiting NCT02968355
48 Study of Natural Killer Immunity During Infections With CMV or AdV After Allogeneic Hematopoietic Stem Cells Recruiting NCT03294824
49 Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection. Recruiting NCT03161444
50 An Open Label Study of IgG Fc Glycan Composition in Human Immunity Recruiting NCT01967238

Search NIH Clinical Center for Chikungunya

Sources

Genetic Tests for Chikungunya

About this section
Sources

Anatomical Context for Chikungunya

About this section

MalaCards organs/tissues related to Chikungunya:

41
Testes, Heart, T Cells, Skin, Brain, Monocytes, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Chikungunya:

19
Joint
Sources

Publications for Chikungunya

About this section

Articles related to Chikungunya:

(show top 50) (show all 4586)
# Title Authors PMID Year
1
Peripheral polyneuropathy associated with Chikungunya virus infection. 38 17
31428990 2019
2
Chikungunya in a kidney transplant recipient: a case report. 38 17
31419273 2019
3
Interferon-inducible protein (IFI) 16 regulates Chikungunya and Zika virus infection in human skin fibroblasts. 38 17
31423125 2019
4
Licensed chikungunya virus vaccine: a possibility? 38
30409444 2019
5
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. 38
30409443 2019
6
Prevalence and identification of arthropod-transmitted viruses in Kassala state, Eastern Sudan. 38
30716013 2019
7
Construction of an efficient genomic editing system with CRISPR/Cas9 in the vector mosquito Aedes albopictus. 38
30311353 2019
8
Comparison of Six Commercial Diagnostic Tests for the Detection of Dengue Virus Non-Structural-1 Antigen and IgM/IgG Antibodies. 38
31240885 2019
9
The phylogenetic approach for viral infectious disease evolution and epidemiology: An updating review. 38
31243773 2019
10
Current status of dengue virus, poliovirus, and chikungunya virus in Pakistan. 38
31251402 2019
11
Chikungunya virus drug discovery: still a long way to go? 38
31177861 2019
12
Understanding the mechanism of Chikungunya virus vector competence in three species of mosquitoes. 38
30913314 2019
13
Mosquito vectors of arboviruses in French Polynesia. 38
31316821 2019
14
Guillain-Barre syndrome and its correlation with dengue, Zika and chikungunya viruses infection based on a literature review of reported cases in Brazil. 38
31220435 2019
15
Entomo-virological surveillance strategy for dengue, Zika and chikungunya arboviruses in field-caught Aedes mosquitoes in an endemic urban area of the Northeast of Brazil. 38
31194961 2019
16
Risk of chikungunya virus transmission associated with European travelers returning from southern Thailand (2008-2015). 38
31228360 2019
17
Sustained Low-Level Transmission of Zika and Chikungunya Viruses after Emergence in the Fiji Islands. 38
31310218 2019
18
Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine. 38
31092567 2019
19
Characterization of antibody response in patients with acute and chronic chikungunya virus disease. 38
31229935 2019
20
Adverse event following live attenuated chikungunya vaccine in a cynomolgus macaque with pre-existing chronic hydrocephalus. 38
30945306 2019
21
Lack of nsP2-specific nuclear functions attenuates chikungunya virus replication both in vitro and in vivo. 38
31163352 2019
22
Epidemiology of Dengue, Chikungunya, and Zika Virus Disease in the U.S. States and Territories, 2017. 38
31436154 2019
23
Development of a theoretical model for the inhibition of nsP3 protease of Chikungunya virus using pyranooxazoles. 38
31366291 2019
24
Genetic Variability of Chikungunya Virus in Southern Mexico. 38
31387277 2019
25
Structures Unveil the Invasion Mechanism of Chikungunya Virus. 38
31221449 2019
26
Genetic Characterization of Chikungunya Virus in Field-Caught Aedes aegypti Mosquitoes Collected during the Recent Outbreaks in 2019, Thailand. 38
31382507 2019
27
'Swimming mosquitoes': a key stepping stone to prevent Dengue, Zika and Chikungunya: an educative experience in Colima, Mexico. 38
31329869 2019
28
Multiplexed Adaptive RT-PCR Based on L-DNA Hybridization Monitoring for the Detection of Zika, Dengue, and Chikungunya RNA. 38
31388071 2019
29
Development of an enzyme-linked immunosorbent assay using recombinant protein antigen for the diagnosis of Chikungunya virus. 38
31194157 2019
30
Structure based virtual screening, 3D-QSAR, molecular dynamics and ADMET studies for selection of natural inhibitors against structural and non-structural targets of Chikungunya. 38
30114965 2019
31
Development of a rapid antiviral screening assay based on eGFP reporter virus of Mayaro virus. 38
31150677 2019
32
The social face of Aedes control: women take the floor in a suburban district of Fortaleza, Brazil. 38
31389545 2019
33
A yellow flag on the horizon: the looming threat of yellow fever to North America. 38
31382047 2019
34
Efficacy of Spinosad Granules and Lambda-Cyhalothrin Contrasts with Reduced Performance of Temephos for Control of Aedes spp. in Vehicle Tires in Veracruz, Mexico. 38
31390780 2019
35
Clinical relevance of Zika symptoms in the context of a Zika Dengue epidemic. 38
31399372 2019
36
Microclimate and Larval Habitat Density Predict Adult Aedes albopictus Abundance in Urban Areas. 38
31190685 2019
37
Detrimental Effects of Induced Antibodies on Aedes aegypti Reproduction. 38
30941675 2019
38
Impact of Temperature Variant on Survival of Aedes albopictus Skuse (Diptera: Culicidae): Implications on Thermotolerance and Acclimation. 38
30977000 2019
39
Development of a bead-based immunoassay using virus-like particles for detection of alphaviral humoral response. 38
30998959 2019
40
RNA processing bodies are disassembled during Old World alphavirus infection. 38
31418676 2019
41
Acute Zika virus infection in an asymptomatic blood donor at the onset of the Puerto Rico epidemic. 38
31407817 2019
42
Systematic identification and characterization of Aedes aegypti long noncoding RNAs (lncRNAs). 38
31434910 2019
43
Dynamics and diversity of bacteria associated with the disease vectors Aedes aegypti and Aedes albopictus. 38
31434963 2019
44
Multi-core-shell composite SnO2NPs@ZIF-8: potential antiviral agent and effective photocatalyst for waste-water treatment. 38
31197665 2019
45
Induction of RNA interference to block Zika virus replication and transmission in the mosquito Aedes aegypti. 38
31103782 2019
46
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases - United States, 2018. 38
31393865 2019
47
Epidemiological profile of Zika, Dengue and Chikungunya virus infections identified by medical and molecular evaluations in Rondonia, Brazil. 38
31432989 2019
48
IL-27 in patients with Chikungunya fever: A possible chronicity biomarker? 38
31075222 2019
49
Metagenomic next-generation sequencing aids the diagnosis of viral infections in febrile returning travellers. 38
31398374 2019
50
Development of a direct reverse-transcription quantitative PCR (dirRT-qPCR) assay for clinical Zika diagnosis. 38
31202908 2019
Sources

Variations for Chikungunya

About this section
Sources

Expression for Chikungunya

About this section
Search GEO for disease gene expression data for Chikungunya.
Sources

Pathways for Chikungunya

About this section

Pathways related to Chikungunya according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.87 UBE2L3 TNF RSAD2 PHB OAS3 MAVS
2
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 13 TNF OAS3 MAVS IL6 IL1B CCL5
3
Human cytomegalovirus infection 37
Show member pathways
 12.8 TNF MAVS IL6 IL1B DDX58 CCL5
4
Cytokine Signaling in Immune system 66
Show member pathways
 12.76 TNF RSAD2 PHB OAS3 IL6 IL1B
5
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 66
Show member pathways
 12.7 TNF MAVS IL6 IL1B DDX58 CCL5
6
Immune response IL-23 signaling pathway 22
Show member pathways
 12.51 TNF IL6 IL1B CCL2
7
Interferon gamma signaling 66
Show member pathways
 12.46 RSAD2 OAS3 DDX58 BST2
8
NF-kappaB Signaling 4
12.32 TNF RSAD2 MAVS IL1B DDX58 CCL5
9
IL-17 Family Signaling Pathways 65
Show member pathways
 12.28 TNF IL6 IL1B CCL2
10
Selenium Micronutrient Network 1
Show member pathways
 12.28 TNF IL6 IL1B CCL5 CCL2
11
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.16 TNF RSAD2 OAS3 IL6 IL1B BST2
12
Fluid shear stress and atherosclerosis 37
12.01 TNF IL1B CCL2
13
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.99 IL6 IL1B CCL5 CCL2
14
Th1 Differentiation Pathway 65
Show member pathways
 11.97 TNF IL6 IL1B
15
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.96 TNF IL6 IL1B
16
Spinal Cord Injury 1
11.96 TNF IL6 IL1B CCL2
17
Interleukin-4 and 13 signaling 66
11.93 TNF IL6 IL1B CCL2
18
TNF signaling pathway 37
11.88 TNF IL6 IL1B CCL5 CCL2
19
AGE-RAGE signaling pathway in diabetic complications 37
11.87 TNF IL6 IL1B CCL2
20
Amoebiasis 37
11.85 TNF IL6 IL1B
21
NF-kappa B signaling pathway 37
11.85 TNF IL1B DDX58
22
Hematopoietic cell lineage 37
11.83 TNF IL6 IL1B
23
Rheumatoid arthritis 37
11.73 TNF IL6 IL1B CCL5 CCL2
24
Pertussis 37
11.71 TNF IL6 IL1B
25
Dendritic Cells Developmental Lineage Pathway 65
11.7 TNF IL6 IL1B
26
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.62 TNF IL6 IL1B
27
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.57 TNF IL6 IL1B CCL5 CCL2
28
Legionellosis 37
11.56 TNF IL6 IL1B
29
MSP-RON Signaling 64
11.49 TNF IL1B CCL2
30
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.46 TNF IL6 IL1B
31
Malaria 37
11.45 TNF IL6 IL1B CCL2
32
African trypanosomiasis 37
11.36 TNF IL6 IL1B
33
Lung fibrosis 1
11.35 TNF IL6 IL1B CCL5 CCL2
34
Prion diseases 37
11.34 IL6 IL1B CCL5
35
IL-10 Pathway 64
11.34 TNF IL6 IL1B
36
Development and heterogeneity of the ILC family 1
11.29 TNF IL6 IL1B
37
Antifolate resistance 37
11.27 TNF IL6 IL1B
38
Cytokines and Inflammatory Response 1
11.23 TNF IL6 IL1B
39
G-protein signaling_RhoB regulation pathway 22
11.14 TNF IL6 IL1B CCL5 CCL2
40
Transcription factor regulation in adipogenesis 1
11.04 TNF IL6
41
Cellular roles of Anthrax toxin 1
11.04 TNF IL1B
42
Overview of nanoparticle effects 1
10.97 TNF IL6
43
G-protein signaling_Rap2B regulation pathway 22
10.96 TNF IL6 IL1B CCL5 CCL2
44
LDL Oxidation in Atherogenesis 64
10.92 TNF IL1B CCL2
45
Interleukin-10 signaling 66
10.71 TNF IL6 IL1B CCL5 CCL2
Sources

GO Terms for Chikungunya

About this section

Biological processes related to Chikungunya according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.97 TNF IL6 IL1B CCL5 CCL2
2 inflammatory response GO:0006954 9.97 TNF NDST1 IL6 IL1B CCL5 CCL2
3 MAPK cascade GO:0000165 9.96 TNF IL1B CCL5 CCL2
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.92 TNF MAVS IL1B BST2
5 cellular response to lipopolysaccharide GO:0071222 9.9 TNF IL6 IL1B CCL2
6 neutrophil chemotaxis GO:0030593 9.86 IL1B CCL5 CCL2
7 regulation of insulin secretion GO:0050796 9.85 TNF IL1B CCL5
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.84 TNF PHB CCL5 CCL2
9 type I interferon signaling pathway GO:0060337 9.83 RSAD2 OAS3 BST2
10 positive regulation of T cell proliferation GO:0042102 9.83 IL6 IL1B CCL5
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 TNF IL6 CCL5
12 cellular response to organic cyclic compound GO:0071407 9.81 TNF IL1B CCL5 CCL2
13 positive regulation of interleukin-6 production GO:0032755 9.78 TNF IL6 IL1B DDX58
14 monocyte chemotaxis GO:0002548 9.77 IL6 CCL5 CCL2
15 positive regulation of interleukin-6 secretion GO:2000778 9.74 MAVS IL1B DDX58
16 negative regulation of neurogenesis GO:0050768 9.73 TNF IL6 IL1B
17 protein kinase B signaling GO:0043491 9.73 TNF IL1B CCL5 CCL2
18 eosinophil chemotaxis GO:0048245 9.72 CCL5 CCL2
19 positive regulation of DNA-binding transcription factor activity GO:0051091 9.72 TNF MAVS IL6 IL1B DDX58
20 positive regulation of chemokine production GO:0032722 9.71 TNF IL6
21 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.71 TNF IL1B
22 negative regulation of lipid catabolic process GO:0050995 9.71 TNF IL1B
23 animal organ morphogenesis GO:0009887 9.71 TNF CCL2
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.71 TNF IL1B
25 cellular response to exogenous dsRNA GO:0071360 9.7 MAVS DDX58
26 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 TNF IL1B
27 positive regulation of tumor necrosis factor secretion GO:1904469 9.7 MAVS DDX58
28 positive regulation of interferon-alpha production GO:0032727 9.7 MAVS DDX58
29 positive regulation of glial cell proliferation GO:0060252 9.7 TNF IL6 IL1B
30 macrophage chemotaxis GO:0048246 9.69 CCL5 CCL2
31 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.69 IL1B DDX58
32 positive regulation of interferon-alpha secretion GO:1902741 9.68 MAVS DDX58
33 negative regulation of lipid storage GO:0010888 9.68 TNF IL6
34 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IL1B
35 response to glucocorticoid GO:0051384 9.67 TNF IL6
36 regulation of establishment of endothelial barrier GO:1903140 9.67 TNF IL1B
37 lipopolysaccharide-mediated signaling pathway GO:0031663 9.67 TNF IL1B CCL5 CCL2
38 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.65 RSAD2 IL6
39 positive regulation of response to cytokine stimulus GO:0060760 9.65 MAVS DDX58
40 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.64 MAVS DDX58
41 positive regulation of interferon-beta secretion GO:0035549 9.63 MAVS DDX58
42 positive regulation of fever generation GO:0031622 9.63 TNF IL1B
43 humoral immune response GO:0006959 9.63 TNF IL6 CCL2
44 defense response to virus GO:0051607 9.63 RSAD2 OAS3 MAVS IL6 DDX58 BST2
45 sequestering of triglyceride GO:0030730 9.61 TNF IL1B
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IL1B
47 positive regulation of neuroinflammatory response GO:0150078 9.58 TNF IL6 IL1B
48 positive regulation of interleukin-8 production GO:0032757 9.56 TNF MAVS IL1B DDX58
49 response to virus GO:0009615 9.43 TNF RSAD2 OAS3 DDX58 CCL5 BST2
50 chronic inflammatory response to antigenic stimulus GO:0002439 9.3 TNF

Molecular functions related to Chikungunya according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 UBE2L3 TNF RSAD2 PHB OAS3 NDST1
2 cytokine activity GO:0005125 9.02 TNF IL6 IL1B CCL5 CCL2
Sources

Sources for Chikungunya

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....